Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business HighlightsPRNewsWire • 08/10/20
Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development ProgressPRNewsWire • 07/16/20
Kodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Society of RetinPRNewsWire • 07/10/20
Kodiak Sciences Inc. (KOD) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 06/05/20
Kodiak Sciences Inc. (KOD) CEO Victor Perlroth on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/13/20
Is Kodiak Sciences (KOD) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 12/25/19
Kodiak Sciences Inc. (KOD) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 12/24/19
Kodiak Sciences Fully Funded And Ready To Potentially Change Wet-AMD TreatmentSeeking Alpha • 12/24/19